TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 1.30nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 1.40nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 1.60nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 1.60nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 1.70nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 2.20nM ΔG°: -49.4kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 2.30nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 3nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
Affinity DataKi: 3.10nM ΔG°: -48.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 4.10nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 4.40nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 4.90nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 5.20nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
Affinity DataKi: 5.30nM ΔG°: -47.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 6.40nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 6.80nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 8.10nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 11nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 12nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 13nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 13nM ΔG°: -45.0kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 14nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 15nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 15.9nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
Affinity DataKi: 20nM ΔG°: -43.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 22nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 22.9nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 26nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
Affinity DataKi: 26nM ΔG°: -43.3kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 27nM ΔG°: -43.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 30nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 34nM ΔG°: -42.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 36nM ΔG°: -42.5kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 37nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 42nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 44nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 47nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 47nMAssay Description:Inhibition of human alpha-thrombinMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 50nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 60nMAssay Description:In vitro binding affinity towards human Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 63nM ΔG°: -41.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair